Venue suggestions

Venue Recommendations

as_is

None. The editor's verdict is "major" and the manuscript is not yet submitted anywhere. The panel's confidence-weighted score of 4.24/5 reflects sound science but unresolved central claims and incomplete reporting that prevent publication at a top-tier venue without revision.

---

after_revision

Nature Neuroscience or Neuron

• Fit: Both are primary venues for mechanistic neurobiology and ALS-relevant protein trafficking. The core contribution — a systematic map of the TDP-43 bipartite NLS and its disruption by K82 acetylation — is exactly the scope these journals target. The TMT proteomics, the K→R mutagenesis panel, and the patient-tissue validation are all at the depth expected.
• Odds after revision: Moderate-to-good (60–70%), conditional on: (i) closing the necessity gap (either with the HDAC/sirtuin manipulation experiment or a credible reframing to sufficiency language); (ii) full PTM-MS reporting and data deposition; (iii) completing the compliance items (Supplementary Tables, fractionation purity, clinical metadata). The editor's letter is constructive and the science is not in doubt; the barrier is completeness and causal clarity, both fixable.
• Why these over others: Both have published related TDP-43 trafficking work and have the editorial bandwidth for the supplementary depth this paper now requires.

EMBO Journal

• Fit: Strong secondary choice. EMBO values mechanistic clarity and rigorous validation; the K82 mutagenesis and acetylated-peptide binding assay fit that bar. The sALS tissue work adds translational weight.
• Odds after revision: Moderate (55–65%). EMBO is slightly more tolerant of incomplete initial reporting if the core experiment is sound, but the necessity gap and PTM-MS reporting gaps will still need closure.

---

alternative

Science Translational Medicine (if the authors emphasize the ac-K82 antibody and sALS biomarker angle)

• Fit: If the paper is reframed to highlight the ac-K82 antibodies as a novel diagnostic tool and the proteasome-acetylation-TDP-43 axis as a therapeutic target, STM's translational scope could accommodate it. However, the current manuscript is fundamentally a mechanism paper, not a biomarker or drug-discovery paper, so this is a stretch.
• Odds: Low (30–40%) unless the framing shifts substantially.

Journal of Neuroscience or Molecular Neurodegeneration

• Fit: Both are solid specialty journals for neurodegenerative disease mechanisms. JNeurosci has high standards but is slightly more forgiving of incomplete initial reporting than Nature-family journals. Molecular Neurodegeneration is explicitly ALS-focused and would value the patient-tissue data.
• Odds after revision: Good (70–75%). These are realistic fallbacks if Nature Neuroscience or Neuron decline, and publication here would be well-received in the ALS community.

bioRxiv (as a preprint server pending journal submission)

• Fit: The manuscript is already at preprint quality. Posting to bioRxiv with a clear statement of the revision plan (e.g., "Revised version addressing necessity experiment and PTM-MS reporting in preparation") would allow the community to engage while the authors complete the work.
• Odds: Certain (100%). This is not an alternative to journal publication but a parallel strategy.

---

Notes on the revision path

The editor's letter is unusually specific and fair. The two major issues are:

1. Necessity vs. sufficiency: The title and abstract claim causation ("initiates … by disrupting"), but the data show only sufficiency. The K82R confound (Fig. 4C–E) is real and the authors deserve credit for having generated the data that reveals it, but it does not resolve the gap. The editor offers two routes: (i) a pharmacological experiment (HDAC/sirtuin inhibition) to test whether raising or lowering K82 acetylation changes the phenotype, or (ii) reframing to sufficiency language. Route (i) is preferred and is feasible; it would materially strengthen the paper. Route (ii) is acceptable but materially weakens the claim and may reduce journal tier.

2. PTM-MS reporting: The discovery step (Figs. 3–5) currently lacks sufficient detail for independent evaluation. Full instrument, search-engine, and FDR reporting, plus data deposition, are non-negotiable for Nature-tier venues.

The compliance items (Supplementary Tables, fractionation purity, clinical metadata, antibody validation) are individually fixable but collectively significant. None alone is grounds for rejection, but together they signal incomplete documentation that a public-review venue cannot overlook.

Realistic timeline: If the authors pursue the HDAC/sirtuin experiment, 2–3 months for completion and resubmission. If they reframe to sufficiency, 2–4 weeks. Either way, Nature Neuroscience or Neuron is realistic after revision.